MDWD - メディウ―ンド （MediWound Ltd.） メディウ―ンドMDWDのチャート
MDWDの企業情報
| symbol | MDWD |
|---|---|
| 会社名 | Mediwound Ltd. （メディウ―ンド） |
| 分野（sector） | Consumer Durables 耐久消費財 |
| 産業（industry） | Specialty Chemicals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing manufacturing and commercializing therapeutics products in the fields of severe burns chronic and other hard-to-heal wounds connective tissue disorders and other indications. The Company''s product NexoBrid is indicated for the removal of dead or damaged tissue known as eschar in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product EscharEx is a topical biological drug which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications. メディウ―ンドはイスラエルのバイオ医薬品会社。重度熱傷、慢性疾患、その他治癒が困難な創傷、膠原病などの分野で有効な治療法がない医療ニ―ズに対応する製品の開発、製造、商業化に従事する。同社のバイオ医薬品｢NexoBrid｣は痂皮の切除用製品として、欧州医薬品庁から承認済みである。 mediwound is a fully-integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds. mediwound’s first innovative biopharmaceutical product, nexobrid®, received marketing authorization from the european medicines agency as well as the israeli and argentinian ministries of health, for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full-thickness thermal burns and was launched in europe israel and argentina. nexobrid represents a new paradigm in burn care management, and clinical trials have demonstrated, with statistical significance, its ability to non-surgically and rapidly remove the eschar earlier and without harming viable tissue. mediwound's second innovative product, escharex®, is a topical biological drug being developed for debridement of chronic and |
| 本社所在地 | 42 Hayarkon Street Yavne 8122745 ISR |
| 代表者氏名 | Stephen T. Wills スティーブン・T・ウィルズ |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +972 8-932-4010 |
| 設立年月日 | 36526 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 76人 |
| url | www.MediWound.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mdwd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -12.75100 |
| 終値（lastsale） | 6.36 |
| 時価総額（marketcap） | 172857416.04 |
| 時価総額 | 時価総額（百万ドル） 165.24730 |
| 売上高 | 売上高（百万ドル） 2.82000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 138.24330 |
| 当期純利益 | 当期純利益（百万ドル） -14.47300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Mediwound Ltd revenues increased 26% to $1.6M. Net loss decreased 1% to $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development net decrease of 65% to $1.2M (expense) General and administrative decrease of 40% to $989K (expense). |
MDWDのテクニカル分析
MDWDのニュース
MediWound: With Expenses Covered, Growth Is Within Reach 2023/05/31 23:14:51 Seeking Alpha
MediWound develops medical solutions for skin and burn conditions and will begin US distribution of its burn solution NexoBrid in Q3 2023. Read why I''m bullish.
MediWound slips after Q1 miss 2023/05/30 19:01:52 Seeking Alpha
MediWound Ltd. (MDWD) lost ~7% Tuesday after announcing its Q1 2023 financials that failed to meet Street forecasts. Read the full story here.
MediWound Ltd. (MDWD) Q1 2023 Earnings Call Transcript 2023/05/30 14:53:10 Seeking Alpha
MediWound Ltd. (NASDAQ:NASDAQ:MDWD) Q1 2023 Earnings Conference Call May 30, 2023 8:30 AM ETCompany ParticipantsMonique Kosse - LifeSci Advisors, IROfer Gonen - Chief Executive OfficerHani…
Earnings Scheduled For May 30, 2023 2023/05/30 12:53:44 Benzinga
Companies Reporting Before The Bell • Gaotu Techedu (NYSE: GOTU ) is projected to report earnings for its first quarter. • UP Fintech Holding (NASDAQ: TIGR ) is likely to report quarterly earnings at $0.03 per share on revenue of $45.06 million. • Elbit Systems (NASDAQ: ESLT ) is expected to report quarterly earnings at $1.73 per share on revenue of $1.39 billion. • Yatra Online (NASDAQ: YTRA ) is estimated to report quarterly loss at $0.02 per share on revenue of $12.87 million. • TH International (NASDAQ: THCH ) is projected to report earnings for its first quarter. • Skyline Champion (NYSE: SKY ) is estimated to report quarterly earnings at $0.93 per share on revenue of $528.22 million. • MediWound (NASDAQ: MDWD ) is likely to report quarterly loss at $0.30 per share on revenue of $5.15 million. • Tremor Intl (NASDAQ: TRMR ) is expected to report earnings for its first quarter. • Huize … Full story available on Benzinga.com
Recap: MediWound Q1 Earnings 2023/05/30 11:15:11 Benzinga
MediWound (NASDAQ: MDWD ) reported its Q1 earnings results on Tuesday, May 30, 2023 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings MediWound missed estimated earnings by 46.67%, reporting an EPS of $-0.44 versus an … Full story available on Benzinga.com
MediWound Ltd. (MDWD) Q4 2022 Earnings Call Transcript 2023/03/16 18:30:04 Seeking Alpha
MediWound Ltd. (NASDAQ:NASDAQ:MDWD) Q4 2022 Earnings Conference Call March 16, 2023 8:30 AM ETCompany ParticipantsMonique Kosse - LifeSci Advisors, IROfer Gonen - Chief Executive…
Mediwound (MDWD) Investor Presentation - Slideshow 2023/03/16 18:14:41 Seeking Alpha
The following slide deck was published by MediWound Ltd.
MediWound names industry veteran as CFO 2023/03/16 11:30:19 Seeking Alpha
MediWound (MDWD) appointed Ms. Hani Luxenburg as its new CFO, effective May 14, 2023, replacing Mr. Boaz Gur-Lavie, who served in the role for last year years.Mr
MediWound: Q4 Earnings Snapshot 2023/03/16 11:28:28 WTOP
YAVNE, Israel (AP) — YAVNE, Israel (AP) — MediWound Ltd. (MDWD) on Thursday reported a loss of $7.5 million in…
MediWound Q4 2022 Earnings Preview 2023/03/15 17:25:55 Seeking Alpha
MediWound (MDWD) is scheduled to announce Q4 earnings results on Thursday, March 16th, before market open.The consensus EPS Estimate is -$0.55 (-266.7% Y/Y) and the consensus…
Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday''s Mid-Day Session 2022/09/22 16:26:59 Benzinga
Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO ) rose 150% to $2.0508 after the company announced it has entered into an exclusive license agreement with GSK for Spero''s late-stage antibiotic asset, tebipenem HBr. Spero Therapeutics will receive $66 million upfront, with potential for future milestone payments, and tiered royalties. HeartBeam, Inc. (NASDAQ: BEAT ) shares gained 34% to $2.12 after dropping 16% on Wednesday. Heartbeam recently announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome and cardiac arrhythmia was issued by the USPTO. ShiftPixy, Inc. (NASDAQ: PIXY ) shares jumped 32.4% to $18.09. ShiftPixy, on Wednesday, announced pricing of $5 million private placement. Inventiva S.A. (NASDAQ: IVA ) gained 23.7% to $4.7250 after the company reported its 2022 first-half financial results and provided a corporate update. Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN ) rose 22.7% to $1.6204. Sonnet BioTherapeutics recently announced progress in Phase 1 dose-escalation trials of SON-1010.
You Should Read This Analysis Before Investing in MediWound Ltd. (NASDAQ:MDWD) 2022/09/22 16:16:00 US Post News
In the current trading session, MediWound Ltd.’s (MDWD) stock is trading at the price of $1.39, a fall of -20.57% over last night’s close. So, the stock is trading at a price that is -65.34% less than its 52-week high of $4.01 and 14.88% better than its 52-week low of $1.21. Based on the past […]
MediWound (NASDAQ:MDWD) Drops on $30M Securities Offerings 2022/09/22 14:18:55 TipRanks
Shares of Biopharmaceutical company MediWound (NASDAQ:MDWD) are tanking today owing to a registered securities offering of ~7.57 million shares and ~9.85 million warrants which will enable accredited investors in the agreement to acquire additional shares of the company. MDWD expects to raise gross proceeds of ~$30.5 million from the offerings. It plans to use the funds to scale up its facilities and for the development of EscharEx. Additionally, it could also use a part of the funds to in-license or invest into or acquire other assets.